TITLE:
Differences between Istradefylline Responders and Non-Responders in Parkinson’s Disease
AUTHORS:
Asako Yoritaka, Nobutaka Hattori
KEYWORDS:
Parkinson’s Disease, Istradefylline, Adenosine A2A Receptor Antagonist, Wearing-Off, Sleepiness
JOURNAL NAME:
Advances in Parkinson's Disease,
Vol.6 No.2,
March
31,
2017
ABSTRACT: Background: Istradefylline is a selective adenosine A2A receptor antagonist approved for Parkinson’s disease (PD) patients with wearing-off symptoms. The Japanese phase III trial showed that 20 mg of orally administrated istradefylline decreased the Off-time. However, istradefylline showed prominent effects in some patients and no benefits in others. We examined the differences in characteristics between responders and non-responders who received 8 weeks of 20 mg/day istradefylline. Methods: Thirty-one patients were enrolled (age, 65.4 [SD 10.4] years; disease duration, 10.4 [SD 6.1] years; daily levodopa dosage, 553.2 [SD 228.7] mg; frequency of levodopa consumption, 4.7 [SD 1.5] times; levodopa equivalent dose, 811.2 [SD 307.5] mg). Results: There were significant differences (p Conclusions: Younger or female patients who are not excessively sleepy during daytime are better candidates for the istradefylline therapy.